Skip to content

Study · Randomized controlled trial · 2020

5 results

Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.

Da Porto A, Casarsa V, Colussi G, Catena C, Cavarape A, Sechi L

Diabetes & metabolic syndrome31 Mar 2020Cited by 56 (Europe PMC)

PMID32289741 (opens in a new tab)DOI10.1016/j.dsx.2020.03.009 (opens in a new tab)PepBankPUB-32289741
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In T2D patients with binge eating disorder, dulaglutide reduced binge eating behaviour more than gliclazide.

    In plain wordsIn patients with diabetes and binge eating disorder, dulaglutide reduced binge eating more than gliclazide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBinge eating behaviour
    Study

    n: not reported in source

    Comparator
    Gliclazide
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1.5 mg weekly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks patients treated with dulaglutide had grater reduction of binge eating behaviour (p < 0.0001), body weight (p < 0,0001), BMI (p < 0.0001), percentage fat mass (p < 0.0001) and HbA1c (p = 0.009) than patients treated with gliclazide.
    1 context sentence
    Summary · context
    This was a pilot open label, prospective controlled study. Inclusion criteria were: Age ≤65, HbA1c between 7.5 and 9% on metformin therapy alone, normal renal function and diagnosis of BED. Patients were randomly assigned to receive either Dulaglutide 1,5 mg/sett or Gliclazide 60 mg for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In T2D patients with binge eating disorder, dulaglutide reduced body weight more than gliclazide.

    In plain wordsIn patients with diabetes and binge eating disorder, dulaglutide reduced weight more than gliclazide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Comparator
    Gliclazide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg weekly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks patients treated with dulaglutide had grater reduction of binge eating behaviour (p < 0.0001), body weight (p < 0,0001), BMI (p < 0.0001), percentage fat mass (p < 0.0001) and HbA1c (p = 0.009) than patients treated with gliclazide.
    1 context sentence
    Summary · context
    This was a pilot open label, prospective controlled study. Inclusion criteria were: Age ≤65, HbA1c between 7.5 and 9% on metformin therapy alone, normal renal function and diagnosis of BED. Patients were randomly assigned to receive either Dulaglutide 1,5 mg/sett or Gliclazide 60 mg for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In T2D patients with binge eating disorder, dulaglutide reduced BMI more than gliclazide.

    In plain wordsIn patients with diabetes and binge eating disorder, dulaglutide reduced BMI more than gliclazide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBMI
    Study

    n: not reported in source

    Comparator
    Gliclazide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg weekly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks patients treated with dulaglutide had grater reduction of binge eating behaviour (p < 0.0001), body weight (p < 0,0001), BMI (p < 0.0001), percentage fat mass (p < 0.0001) and HbA1c (p = 0.009) than patients treated with gliclazide.
    1 context sentence
    Summary · context
    This was a pilot open label, prospective controlled study. Inclusion criteria were: Age ≤65, HbA1c between 7.5 and 9% on metformin therapy alone, normal renal function and diagnosis of BED. Patients were randomly assigned to receive either Dulaglutide 1,5 mg/sett or Gliclazide 60 mg for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In T2D patients with binge eating disorder, dulaglutide reduced percentage fat mass more than gliclazide.

    In plain wordsIn patients with diabetes and binge eating disorder, dulaglutide reduced body fat percentage more than gliclazide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreasePercentage fat mass
    Study

    n: not reported in source

    Comparator
    Gliclazide
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.5 mg weekly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks patients treated with dulaglutide had grater reduction of binge eating behaviour (p < 0.0001), body weight (p < 0,0001), BMI (p < 0.0001), percentage fat mass (p < 0.0001) and HbA1c (p = 0.009) than patients treated with gliclazide.
    1 context sentence
    Summary · context
    This was a pilot open label, prospective controlled study. Inclusion criteria were: Age ≤65, HbA1c between 7.5 and 9% on metformin therapy alone, normal renal function and diagnosis of BED. Patients were randomly assigned to receive either Dulaglutide 1,5 mg/sett or Gliclazide 60 mg for 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In T2D patients with binge eating disorder, dulaglutide reduced HbA1c more than gliclazide.

    In plain wordsIn patients with diabetes and binge eating disorder, dulaglutide lowered HbA1c more than gliclazide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Comparator
    Gliclazide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg weekly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks patients treated with dulaglutide had grater reduction of binge eating behaviour (p < 0.0001), body weight (p < 0,0001), BMI (p < 0.0001), percentage fat mass (p < 0.0001) and HbA1c (p = 0.009) than patients treated with gliclazide.
    1 context sentence
    Summary · context
    This was a pilot open label, prospective controlled study. Inclusion criteria were: Age ≤65, HbA1c between 7.5 and 9% on metformin therapy alone, normal renal function and diagnosis of BED. Patients were randomly assigned to receive either Dulaglutide 1,5 mg/sett or Gliclazide 60 mg for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.